Alivus Life Sciences Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Alivus Life Sciences Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹720
Per ShareLot Size
20 Shares
Minimum Investment
₹14,400
Issue Size
₹1,497.85 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Alivus Life Sciences Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Issue Type
Book Building
ISIN
INE03Q201024
About the Company
Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients ("APIs") in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes. The Company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. It is also increasingly providing contract development and manufacturing operations ("CDMO") services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It is a research and development ("R&D")-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where it believes there is growth potential in the future.
Industry Overview
The global API market was estimated to be around US$181.3 billion in FY 2020 and is expected to grow at a CAGR of 6.2% to reach to about US$259.3 billion by FY 2026. The Indian API industry has been on a high growth trajectory over the past few decades. The Indian bulk drug industry, ranked third in the world, has grown at a CAGR of around 9% over FY 2016-2020. It is further expected to expand and grow at a CAGR of around 9.6% during FY 2021-2026, signifying its future potential and evolving global importance. The API supply chain is shaped by changing demand in the pharmaceutical industry, with price and regulatory enforcement being two of the most significant drivers of change.
Company History
Glenmark Life Sciences Limited was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited' pursuant to a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC.
Products & Services
- The company is a leading developer and manufacturerof select high value, non-commoditized APIs in chronic therapeutic areas, including CVS, CNS, pain management and diabetes
- The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infective and other therapeutic areas.
Growth Strategy
- Expand the Geographic Focus, API Portfolio and Scope of its Operations
- Grow its CDMO Business
- Expand its Production Capacities
- Improving Financial Performance through Focus on Operational Efficiencies
Customer Base
Glenmark, Teva Pharmaceutical Industries, Torrent Pharmaceuticals, Aurobindo Pharma, Krka and another company which is a global leader in generic pharmaceuticals and biosimilars.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is Rs. 2 each. Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each. Anchor Investor offer price: Rs. 720 per Equity share. The Offer Price is 360 times the face value.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Leadership in select high value, non-commoditized APIs in chronic therapeutic areas;
- Strong relationships with leading global generic companies;
- Quality-focused compliant manufacturing and R&D infrastructure;
- Strong focus on sustainability in operations;
- Cost leadership across products through careful monitoring and continuous effort;
- Any manufacturing or quality control problems may subject us to regulatory action, damage its reputation and have an adverse effect on its business, results of operations, financial condition and cash flows.
- Company's business is dependent on the sale of its products to its key customers, and the loss of one or more such customers, the deterioration of their financial condition or prospects, or a reduction in their demand for its products could adversely affect its business, results of operations, financial condition and cash flows.
- Company derive a significant portion of its revenue from its API business, of which a limited number of therapeutic categories and key products generate a significant portion of its total revenue, and its business may be adversely affected if its API business or products in these therapeutic categories or its key products do not perform as well as expected or if substitute products become available or gain wider market acceptance.
- Company's manufacturing and R&D facilities are located in the Indian states of Gujarat and Maharashtra. A slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any delay, interruption or reduction in the supply of raw materials to manufacture its products may adversely affect its business, results of operations, financial condition and cash flows.